Low-dose of caffeine alleviates high altitude pulmonary edema via regulating mitochondrial quality control process in AT1 cells

Liuyang Tian, Zhilong Jia, Yan Yan, Qian Jia, Wenjie Shi, Saijia Cui, Huining Chen, Yang Han, Xiaojing Zhao, Kunlun HeFrontiers in Pharmacology 2023 · DOI

Abstract

Backgrounds: High-altitude pulmonary edema (HAPE) is a life-threatening disease without effective drugs. Caffeine is a small molecule compound with antioxidant biological activity used to treat respiratory distress syndrome. However, it is unclear whether caffeine plays a role in alleviating HAPE. Methods: We combined a series of biological experiments and label-free quantitative proteomics analysis to detect the effect of caffeine on treating HAPE and explore its mechanism in vivo and in vitro. Results: Dry and wet weight ratio and HE staining of pulmonary tissues showed that the HAPE model was constructed successfully, and caffeine relieved pulmonary edema. The proteomic results of mice lungs indicated that regulating mitochondria might be the mechanism by which caffeine reduced HAPE. We found that caffeine blocked the reduction of ATP production and oxygen consumption rate, decreased ROS accumulation, and stabilized mitochondrial membrane potential to protect AT1 cells from oxidative stress damage under hypoxia. Caffeine promoted the PINK1/parkin-dependent mitophagy and enhanced mitochondrial fission to maintain the mitochondria quality control process. Conclusion: Low-dose of caffeine alleviated HAPE by promoting PINK1/parkin-dependent mitophagy and mitochondrial fission to control the mitochondria quality. Therefore, caffeine could be a potential treatment for HAPE.

Introduction

High-Altitude Pulmonary Edema (HAPE) is a severe, life-threatening condition characterized by fluid accumulation in the lungs when individuals ascend rapidly to altitudes above 2,500 meters. The lack of oxygen (hypoxia) causes excessive pulmonary vasoconstriction and damages the alveolar-capillary barrier. While drugs like acetazolamide and nifedipine are currently used, their effectiveness is often inconsistent or limited by side effects.

Research published in Frontiers in Pharmacology explores a surprisingly accessible potential treatment: low-dose caffeine. While caffeine is known for its antioxidant properties in treating respiratory distress syndrome (RDS) in infants, its specific role in HAPE—and the underlying molecular mechanisms—remained largely unexplored until this study.

Methods and Proteomic Analysis

The researchers employed a dual-track approach combining in vivo animal models and in vitro cellular analysis:

  • Animal Model: C57BL/6 mice were placed in a hypobaric hypoxic chamber simulating an altitude of 5,500 meters for three days. One group received a "human equivalent" low dose of caffeine (2.5 mg/kg/day) via oral gavage.
  • Cellular Model: Type I alveolar epithelial (AT1) cells—the cells responsible for gas exchange and fluid reabsorption in the lung—were exposed to 1% oxygen to simulate high-altitude conditions.
  • Proteomics: The team used label-free quantitative proteomics (LC-MS/MS) to identify protein regulation changes in lung tissue under hypoxia versus caffeine treatment. This generated a massive dataset detecting 64,300 unique peptides and 7,571 proteins.
  • Bioenergetics: Seahorse XFe/XF24 analyzers were used to measure the Oxygen Consumption Rate (OCR) and ATP production, providing a real-time look at mitochondrial health.

Key Insights: The Mitochondrial Mechanism

Proteomic clustering revealed that the most significant changes occurred in the mitochondria, specifically within the oxidative phosphorylation (OXPHOS) pathways. Under hypoxia, mitochondria become damaged and leak Reactive Oxygen Species (ROS), which further damages the cell.

Graphical abstract illustrating how caffeine regulates mitochondrial quality control to alleviate HAPE.

Caffeine was found to activate PINK1/Parkin-mediated mitophagy, a process that identifies and "recycles" broken mitochondria before they can cause harm. Additionally, caffeine promoted mitochondrial fission (via the DRP1 protein). In this context, fission acts as a quality control mechanism, allowing the cell to segregate damaged parts of the mitochondrial network for disposal. By stabilizing ATP levels, caffeine ensures the ion pumps responsible for keeping the lungs dry remain functional.

Key Results

  • Edema Relief: Caffeine treatment resulted in a significant reduction in the lung's dry-to-wet weight ratio and improved lung tissue structure as seen in HE staining.
  • ROS Reduction: Confocal microscopy showed that caffeine significantly suppressed the accumulation of cytoplasmic and mitochondrial ROS induced by hypoxia.
  • Metabolic Shift: Caffeine neutralized the hypoxia-induced decrease in mitochondrial ATP production and stabilized the mitochondrial membrane potential (MMP).
  • Dose Relevance: The study emphasized that these effects were achieved at a low dose (15 μM in cells, ~2.5 mg/kg in mice), suggesting that the benefit comes from specific signaling pathways rather than a general stimulant effect.

Limitations and Future Directions

The authors acknowledge several areas for further exploration. This study focused heavily on AT1 cells; however, HAPE also involves vascular endothelial cells and AT2 cells, whose responses to caffeine require verification. Furthermore, while the study highlights the PINK1/Parkin pathway, it does not fully explore whether caffeine’s effects are mediated through traditional adenosine receptors ($A_1, A_{2A}$).

Finally, while the mouse dose translates to a standard cup of coffee, human clinical trials are necessary to determine if "pre-loading" with caffeine or using it as a rescue therapy is effective for mountaineers or high-altitude workers.

Conclusion

Low-dose caffeine significantly reduces lung edema in hypoxic environments by activating the PINK1/Parkin pathway. This mechanism promotes the clearance of damaged mitochondria and maintains energy production in Type I alveolar epithelial cells, offering a potential new therapeutic strategy for high-altitude illness.

Summary updated

Abstract

<b>Backgrounds:</b> High-altitude pulmonary edema (HAPE) is a life-threatening disease without effective drugs. Caffeine is a small molecule compound with antioxidant biological activity used to treat respiratory distress syndrome. However, it is unclear whether caffeine plays a role in alleviating HAPE. <b>Methods:</b> We combined a series of biological experiments and label-free quantitative proteomics analysis to detect the effect of caffeine on treating HAPE and explore its mechanism <i>in vivo</i> and <i>in vitro</i>. <b>Results:</b> Dry and wet weight ratio and HE staining of pulmonary tissues showed that the HAPE model was constructed successfully, and caffeine relieved pulmonary edema. The proteomic results of mice lungs indicated that regulating mitochondria might be the mechanism by which caffeine reduced HAPE. We found that caffeine blocked the reduction of ATP production and oxygen consumption rate, decreased ROS accumulation, and stabilized mitochondrial membrane potential to protect AT1 cells from oxidative stress damage under hypoxia. Caffeine promoted the PINK1/parkin-dependent mitophagy and enhanced mitochondrial fission to maintain the mitochondria quality control process. <b>Conclusion:</b> Low-dose of caffeine alleviated HAPE by promoting PINK1/parkin-dependent mitophagy and mitochondrial fission to control the mitochondria quality. Therefore, caffeine could be a potential treatment for HAPE.
BibTeX
@inproceedings{tian2023low,
  author = {Liuyang Tian and Zhilong Jia and Yan Yan and Qian Jia and Wenjie Shi and Saijia Cui and Huining Chen and Yang Han and Xiaojing Zhao and Kunlun He},
  title = {{Low-dose of caffeine alleviates high altitude pulmonary edema via regulating mitochondrial quality control process in AT1 cells}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1155414},
}
Figure